Objective-The goal of this study was to determine whether inhibition of transient receptor potential canonical (TRPC) channels underlies attenuation of angiotensin II (Ang II)-induced vasoconstriction by phosphodiesterase (PDE) 3 inhibition. Methods and Results-Pretreatment of rat thoracic aorta with cilostazol, a selective PDE3 inhibitor, suppressed vasoconstriction induced by Ang II but not that induced by KCl. The Ang II-induced contraction was largely dependent on Ca 2ϩ influx via receptor-operated cation channels. Cilostazol specifically suppressed diacylglycerol-activated TRPC channels (TRPC3/TRPC6/TRPC7) through protein kinase A (PKA)-dependent phosphorylation of TRPC channels in HEK293 cells. In contrast, we found that phosphorylation of TRPC6 at Thr69 was essential for the suppression of Ang II-induced Ca 2ϩ influx by PDE3 inhibition in rat aortic smooth muscle cells (RAoSMCs). Cilostazol specifically induced phosphorylation of endogenous TRPC6 at Thr69. The endogenous TRPC6, but not TRPC3, formed a ternary complex with PDE3 and PKA in RAoSMCs, suggesting the specificity of TRPC6 phosphorylation by PDE3 inhibition. Furthermore, inhibition of PDE3 suppressed the Ang II-induced contraction of reconstituted ring with RAoSMCs, which were abolished by the expression of a phosphorylation-deficient mutant of TRPC6. Conclusion-PKA-mediated phosphorylation of TRPC6 at Thr69 is essential for the vasorelaxant effects of PDE3 inhibition against the vasoconstrictive actions of Ang II. (Arterioscler Thromb Vasc Biol. 2011;31:2278-2286.)
P eripheral vascular tone is controlled mainly by agonist stimulation via the sympathetic nerve system, the reninangiotensin-aldosterone system, and inherent myogenic contraction. 1 Increase in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) in response to neurotransmitters and hormones triggers contraction of vascular smooth muscle cells (VSMCs). 2 Stimulation of G q protein-coupled receptor activates phospholipase C and induces production of 2 second messengers, inositol-1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). 3 IP 3 mobilizes Ca 2ϩ release from the internal Ca 2ϩ stores through stimulation of IP 3 receptors, leading to a transient increase in [Ca 2ϩ ] i . Depletion of Ca 2ϩ stores by IP 3 -mediated Ca 2ϩ release then induces subsequent Ca 2ϩ entry through activation of store-operated Ca 2ϩ channels. 4 A variety of evidence has implied the important roles of store-operated Ca 2ϩ channels in vascular tone regulation. 5 In contrast, DAG is primarily thought to activate protein kinase C, but it also plays a more direct role in activating Ca 2ϩ entry, 6 and recent reports have implied that DAG-mediated Ca 2ϩ influx also participates in vascular tone regulation. [7] [8] [9] However, it is unclear which pathway is involved in agonistinduced contraction of aortic VSMCs.
Cilostazol, a selective phosphodiesterase (PDE) 3 inhibitor, is clinically used as an antiplatelet drug and is also applicable to patients with intermittent claudication and arteriosclerosis obliteration. 10 -12 Cilostazol has been shown to induce vascular relaxation through a protein kinase A (PKA)-dependent decrease in [Ca 2ϩ ] i of VSMCs. 13, 14 Several PKA target proteins responsible for suppression of agonist-induced vascular contraction have been reported. [15] [16] [17] [18] For example, PKA phosphorylates myosin light chain kinase (MLCK), which leads to decrease in myosin light chain phosphorylation levels. 15 PKA also phosphorylates G protein-coupled receptor kinase 2 and regulator of G protein signaling proteins, enhancing the inactivation of G␣ qmediated signaling in VSMCs and resulting in suppression of agonist-induced vasoconstriction. 16 -18 Thus, the phosphorylation of these targets can explain the mechanism of PKAdependent vasodilation. However, it is still unclear why cilostazol induces a decrease in [Ca 2ϩ ] i of VSMCs through PKA activation.
The transient receptor potential channel was originally identified in a Drosophila visual transduction mutation, trp, in which the receptor potential is transient on light perception. 19 The canonical subfamily transient receptor potential canonical (TRPC) channels are thought as putative candidates for receptor-operated cation channels (ROCCs). 20 Among the 7 members of vertebrate TRPCs (TRPC1 to TRPC7), TRPC2, TRPC3, TRPC6, and TRPC7 have been reported to be activated by DAG. 21, 22 Sustained cation influx induced by activation of DAG-activated TRPC channels leads to membrane depolarization, resulting in increase of [Ca 2ϩ ] i through activation of voltage-dependent L-type Ca 2ϩ channels (VDCCs). 22, 23 In addition, DAG-activated TRPC channels associate with the Na ϩ /Ca 2ϩ exchanger, and TRPCmediated Na ϩ influx results in a shift of Na ϩ /Ca 2ϩ exchanger operation to the reverse mode (ie, Ca 2ϩ influx). 24, 25 The resultant Ca 2ϩ influx mediated by DAG-activated cation influx through TRPC channels are required for muscle contraction 7, 8 and gene expression. 23, 26 The activity of DAG-activated TRPC channels is negatively regulated by their phosphorylation. [27] [28] [29] [30] Protein kinase C has been implicated in the suppression of TRPC3 channel activity via phosphorylation of human TRPC3 at Ser712, and protein kinase G (PKG)-dependent phosphorylation has been shown to suppress store-operated Ca 2ϩ entry in TRPC3expressing HEK293 cells through phosphorylation of human TRPC3 at Thr11 and Ser263. [27] [28] [29] In addition, PKG-dependent phosphorylation of rodent TRPC6 at Thr69 has been shown to mediate nitric oxide-dependent reduction of TRPC6 channel activity in VSMCs. 30 As the inhibition of TRPC6 reduces agonist-induced membrane depolarization in VSMCs, the nitric oxide-mediated inhibition of TRPC6 channels may be partially involved in the mechanism of endothelium-dependent vasodilation. Activation of PKA by stimulation of the ␤ 2 adrenergic receptor or inhibition of PDE3 is known to induce endotheliumindependent vascular relaxation. However, it is unknown whether activation of PKA suppresses vasoconstriction through inhibition of TRPC channels.
In this study, we demonstrated that PKA-mediated phosphorylation of TRPC6 channels at Thr69 underlies suppression of agonist-induced contraction of aortic VSMCs by PDE3 inhibition. We further demonstrated the molecular mechanism underlying selective phosphorylation of TRPC6 at Thr69 by PDE3 inhibition in rat aortic smooth muscle cells (RAoSMCs).
Methods
The supplemental materials (available online at http://atvb.ahajournals.org) provide expanded descriptions.
Isometric Force Measurements
Rats were anesthetized with sodium pentobarbital (50 mg/kg IP), and the descending thoracic aorta was carefully isolated and cut into 3-mm-long rings. The rings were stretched to a resting tension of 1.5g. We confirmed that pretreatment with PDE3 inhibitors did not affect the resting tension.
Measurement of [Ca 2؉ ] i and Rho Activity, Electrophysiology, Immunoprecipitation, and Western Blot Analyses
Measurement of [Ca 2ϩ ] i and Rho activity, patch clamp recording of HEK293 cells, immunoprecipitation of green fluorescent protein (GFP)-fused proteins, and Western blot analyses were performed as described previously. 30, 31, 32 
Production of a Reconstituted Ring and Measurement of Tension
Production of a reconstituted ring and measurement of tension were performed as described previously. 33 The cultured primary RAoSMCs were collected with trypsinization and transfected with pCIneo vector encoding wild-type TRPC6 or TRPC6-Thr69Ala mutant and pEGFP-N1 using electroporation (1400 V, 10 msϫ3, Digital-Bio). Cell suspensions were mixed with the culture medium (5ϫ10 6 cells/mL) containing 0.6 mg/mL type I collagen (Cellmatrix Type I-P). The mixture (100 L, 0.5ϫ10 6 cells) was placed around a silicone column (ϭ2 mm), which was attached on the center of the silicone disc (ϭ8 mm). After the collagen gel became solid, the culture medium was added and cultured for 24 to 48 hours. The ring preparation thus obtained was used for measurements of isometric tension development. The transfection efficiency of electroporation was 70Ϯ5%, determined by counting GFP-positive RAoSMCs. Tension recordings are described in the supplemental materials.
Statistical Analysis
The results are shown as meanϮSEM. All experiments were repeated at least 3 times. Statistical comparisons were made with the 2-tailed Student t test or analysis of variance followed by the Student-Newman-Keuls procedure, with significance imparted at probability values Ͻ0.05.
Results

Suppression of Agonist-Induced Vasoconstriction by PDE3 Inhibition
Treatment of rat thoracic aorta with G q protein-coupled receptor agonists (angiotensin II [Ang II], phenylephrine, and U46619) increased the tension of aortic rings, which was significantly suppressed by pretreatment with cilostazol in a concentration-dependent manner ( Figure 1A to 1C). Cilostazol suppressed vasoconstriction induced by Ang II more selectively than phenylephrine and U46619. Cilostazol did not suppress KCl-induced contraction ( Figure 1D ), indicating that cilostazol does not inhibit voltage-dependent Ca 2ϩ channels. In addition, the Ang II-induced contraction was markedly reduced by the removal of extracellular Ca 2ϩ , and the effects of cilostazol were abolished in extracellular Ca 2ϩ -free solution ( Figure 1E and 1F). Cilostazol-induced suppression of Ang II contraction in Ca 2ϩ -containing solution was not affected by the removal of endothelium ( Figure 1G ). Milrinone, another PDE3-selective inhibitor, also suppressed Ang II-induced contraction (Supplemental Figure I) . These results suggest that PDE3 inhibition suppresses agonist-induced Ca 2ϩ influx in aortic smooth muscle cells. The Ang IIinduced contraction was completely suppressed by CV11974, an Ang II type 1 receptor antagonist ( Figure 1H ). Further-more, the suppression of Ang II-induced contraction by cilostazol was abolished by inhibitors of ROCCs (SK&F96365) and VDCCs (nitrendipine) but not by an Na ϩ /Ca 2ϩ exchanger (KB-R7943). As activation of ROCCs reportedly induces membrane depolarization, 23,34 these results suggest that PDE3 inhibition suppresses agonist-induced Ca 2ϩ influx through VDCCs by inhibiting ROCCs.
Cilostazol Inhibits DAG-Activated TRPC Channels
TRPC channels are believed to be a molecular candidate of ROCCs. 20 Among 7 TRPC homologues, TRPC3, TRPC6, and TRPC7 proteins (TRPC3/6/7) are expressed in aorta and function as a DAG-activated cation channels in VSMCs. 35 Cilostazol did not affect ATP-induced Ca 2ϩ release from the intracellular Ca 2ϩ store but significantly suppressed Ca 2ϩ influx-mediated increases in [Ca 2ϩ ] i in TRPC3-, TRPC6-, or TRPC7-expressing HEK293 cells ( Figure 2 ). The IC 50 values of inhibition by cilostazol were 0.75Ϯ0.06 mol/L (for TRPC3), 0.73Ϯ0.24 mol/L (for TRPC6), and 0.71Ϯ0.04 mol/L (for TRPC7). Cilostazol also suppressed Ca 2ϩ influx-mediated increases in [Ca 2ϩ ] i induced by 1-oleoyl-2-acetyl-snglycerol (OAG) in TRPC3-, TRPC6-, or TRPC7-expressing cells, with IC 50 values being 0.61Ϯ0.19, 0.68Ϯ0.18, and 0.69Ϯ0.22 mol/L, respectively (Supplemental Figure II) . However, ATP-induced Ca 2ϩ influx through TRPC5 channels, which is believed to be insensitive to DAG, and store-operated Ca 2ϩ influx induced by ionomycin were not suppressed by cilostazol (Supplemental Figure III) . These results suggest that inhibition of PDE3 specifically suppresses agonist-induced Ca 2ϩ influx through DAG-activated TRPC channels.
Involvement of Phosphorylation of TRPC6 at Thr69 in Suppression of TRPC6 Channel Activity by PDE3 Inhibition
As more than 15 minutes of pretreatment with cilostazol was required for the significant suppression of TRPC6-mediated Ca 2ϩ influx induced by ATP or OAG (Supplemental Figure  IV) , cilostazol may not directly inhibit TRPC6 channel activity. In addition, localization of GFP-fused TRPC3 (TRPC3-GFP) and TRPC6 (TRPC6-GFP) proteins on the plasma membrane were not affected by cilostazol treatment (Supplemental Figure V) . These results suggest that PDE3 inhibition did not change the membrane localization of TRPC proteins. Takahashi et al has reported that PKG-dependent phosphorylation of TRPC6 at Thr69 suppresses TRPC6 channel activity. 30 As PKA and PKG recognize a similar substrate sequence, 36 we next examined the involvement of TRPC6 phosphorylation at Thr69 in suppression of TRPC6 channel activity by PDE3 inhibition. The Ca 2ϩ influxmediated [Ca 2ϩ ] i increase induced by OAG was suppressed by cilostazol pretreatment in wild-type TRPC6 (TRPC6-wt)expressing cells, whereas the suppression of OAG-mediated Ca 2ϩ influx by cilostazol was completely abolished in TRPC6-Thr69Ala-expressing cells (Supplemental Figure VI) . The inhibition of TRPC6-mediated Ca 2ϩ influx by cilostazol was also abolished by cotreatment with KT5720, a PKA inhibitor, but not by KT5823 (a PKG inhibitor) or Go6976 (a protein kinase C inhibitor) (Supplemental Figure VII) . In addition, treatment with 8-Br-cAMP and forskolin significantly suppressed Ca 2ϩ influx-mediated [Ca 2ϩ ] i increases induced by OAG stimulation in TRPC6-wt-expressing cells, whereas both PKA activators did not suppress OAG-induced [Ca 2ϩ ] i increases in TRPC6-Thr69Ala-expressing cells (Supplemental Figure VI ). Furthermore, stimulation of muscarinic receptor with carbachol induced inward currents in TRPC6wt-expressing cells; these currents were completely suppressed by the pretreatment with cilostazol ( Figure 3A to 3C). The suppression of TRPC6-induced currents by cilostazol was abolished in cells expressing TRPC6-Thr69Ala ( Figure  3D ). These results suggest that PKA-dependent phosphorylation of TRPC6 at Thr69 underlies inhibition of TRPC6 channel activity by PDE3 inhibition.
PKA-Dependent Phosphorylation of TRPC6 by PDE3 Inhibition
We have recently generated an anti-phospho-TRPC6 (Thr69) antibody 37 and found that activation of PKA by the treatment with forskolin and cilostazol dramatically increased the phosphorylation of TRPC6 at Thr69 in TRPC6-wt-expressing cells, which was not observed in TRPC6-Thr69Alaexpressing cells ( Figure 3E ). This result suggests the specific recognition of Thr69 phosphorylation by this antibody. Treatment of HEK293 cells with cilostazol increased TRPC6 phosphorylation levels Ϸ1.5-fold, which was completely suppressed by cotreatment with KT5720. Treatment with cilostazol gradually increased TRPC6 phosphorylation levels ( Figure 3F) . The time course of this phosphorylation was consistent with the time of pretreatment required to obtain the inhibition of TRPC6-mediated Ca 2ϩ influx with cilostazol (Supplemental Figure IV) . Although cilostazol completely suppressed TRPC6-mediated Ca 2ϩ influx, as in the case of forskolin (Supplemental Figure VI) , the extent of TRPC6 phosphorylation by cilostazol was much weaker than that by forskolin. However, phosphorylation levels of membranelocalized TRPC6 proteins induced by cilostazol were similar to those induced by forskolin ( Figure 3G ). These results suggest that phosphorylation of plasma membrane-localized TRPC6 proteins is essential for suppression of TRPC6 channel activity by PDE3 inhibition.
Phosphorylation of TRPC6 at Thr69 Is Essential for Suppression of Ang II-Induced Ca 2؉ Influx by PDE3 Inhibition in RAoSMCs
We next examined which endogenous TRPC subtype(s) is involved in Ang II-induced Ca 2ϩ influx in RAoSMCs. Although Ang II-induced Ca 2ϩ release was not suppressed by the knockdown of TRPC3/6/7, the Ca 2ϩ -influx-mediated Ca 2ϩ response induced by Ang II was suppressed by knockdown of TRPC6 but not of TRPC3 and TRPC7 ( Figure 4A and 4B). Pretreatment with cilostazol significantly reduced Ca 2ϩ influx-mediated Ca 2ϩ responses induced by Ang II, which was abolished by TRPC6 knockdown. We found that TRPC3 and TRPC6 proteins were actually expressed in RAoSMCs, and expression levels of TRPC proteins were actually suppressed by siRNA treatment ( Figure 4C ). Human TRPC3 has 2 sites (Thr11 and Ser263) phosphorylated by PKG or PKA, and Ser263 (position 2), but not Thr11 (position 1), is conserved in rodent TRPC3/6/7 proteins (Supplemental Figure VI) . As the expression of mouse TRPC3 mutant (Ser251Ala) abolished the suppression of OAG-induced Ca 2ϩ response by cilostazol, position 2 may be involved in suppression of TRPC3 channel activity by PDE3 inhibition. However, pretreatment of RAoSMCs with cilostazol actually induced phosphorylation of TRPC6 at Thr69 (position 1) but did not induce phosphorylation of TRPC3/6/7 at Ser (position 2), although forskolin cotreatment induced phosphorylation of these sites ( Figure 4D ). These results suggest that PDE3 inhibition suppresses Ang II-induced Ca 2ϩ influx via local PKA-mediated phosphorylation of TRPC6 at Thr69 in RAoSMCs. 
Formation of the TRPC-PKA-PDE3 Signal Complex in the Plasma Membrane
We further examined whether DAG-activated TRPC channels functionally interact with PKA and PDE3. TRPC3-GFP, TRPC6-GFP, and farnesylation signal-encoding GFP proteins are predominantly expressed in crude membrane fraction of HEK293 cells, whereas PKA is predominantly expressed in cytosol. Immunoprecipitation of GFP-containing proteins revealed that endogenous PDE3A could associate with TRPC3-GFP and TRPC6-GFP but not with farnesylation signal-encoding GFP proteins. In addition, PKA catalytic subunit also associated with TRPC3-GFP and TRPC6-GFP ( Figure  5A ). Treatment with cilostazol actually induced phosphorylation of TRPC3/6/7 at Ser (position 2) ( Figure 5B ). These results suggest that TRPC3/6/7 could form a signal complex with PDE3 and PKA beneath the plasma membrane in HEK293 cells. However, endogenous TRPC6 associated with PDE3A and PKA more potently than TRPC3 in RAoSMCs ( Figure 5C ), suggesting that endogenous TRPC6 preferentially forms a ternary complex with PDE3 and PKA in RAoSMCs. 
Requirement of TRPC6 Phosphorylation for Cilostazol-Induced Suppression of Vasoconstriction Induced by Ang II in VSMC
To examine the functional relevance of TRPC6 phosphorylation at Thr69 to the vasodilating effect of cilostazol, we examined the effects of TRPC6-Thr69Ala in RAoSMCs. Treatment of RAoSMCs with Ang II induced a transient increase in [Ca 2ϩ ] i , which was significantly suppressed by pretreatment with cilostazol ( Figure 6A and 6B) . Overexpression of TRPC6-wt slightly enhanced the Ang II-induced Ca 2ϩ response, which was also suppressed by cilostazol. In contrast, overexpression of TRPC6-Thr69Ala abolished the suppression of Ang II-induced Ca 2ϩ response by cilostazol pretreatment. We next examined the contractile response of the aortic rings reconstituted from RAoSMCs. Treatment of reconstituted aortic ring with Ang II induced contraction, which was significantly attenuated by pretreatment with cilostazol in the vector (GFP)-expressing rings ( Figure 6C and 6D) . In contrast, the expression of TRPC6-Thr69Ala abolished the suppression of Ang IIinduced contraction by cilostazol pretreatment. A dominant-negative mutant of TRPC6 (TRPC6-3A) also abolished the cilostazol-induced suppression of Ang IIinduced contraction (Supplemental Figure VIII) . These results suggest that the phosphorylation of TRPC6 at Thr69 is required for the suppression of Ang II-induced contraction by cilostazol in RAoSMCs.
Discussion
In excitable cells, one of the main functions of receptor-activated TRPC channels is to induce membrane depolarization through sustained cation influx by receptor stimulation. 23, 34 The membrane depolarization subsequently induces activation of VDCCs, leading to activation of Ca 2ϩ -dependent signaling required for muscle contraction. We revealed that inhibition of ROCCs and VDCCs significantly reduced the Ang II-induced contraction of rat thoracic aorta (Figure 1 ), suggesting that the VDCC-mediated Ca 2ϩ influx via TRPCmediated membrane depolarization is involved in Ang IIinduced contraction of rat thoracic aorta. In contrast, as the magnitude of the suppression by cilostazol of phenylephrineand U46619-induced vasoconstriction was smaller than that of Ang II-induced vasoconstriction, and U46619-induced contraction of reconstituted rings was weakly (not significantly) suppressed by PDE3 inhibition (Supplemental Figure  VIII) . These results suggest that Ang II preferentially induces DAG-mediated Ca 2ϩ influx in aortic VSMCs. We have shown the critical involvement of TRPC6 channels in Ang II-induced vasoconstriction through analyzing the mechanism of vasodilation by PDE3 inhibition. The PDE3 inhibition specifically suppresses DAG-mediated (but not IP 3 -mediated and store-operated) Ca 2ϩ influx through PKA-dependent phosphorylation of TRPC3/6/7. TRPC proteins are known to function not only as a Ca 2ϩ -permeable channel-forming subunit but also as a scaffold protein to form the Ca 2ϩ signaling complex. 38 For example, TRPC3 channels are reported to associate with several signaling molecules, such as IP 3 receptors, calmodulin, vesicle-associated membrane protein 2, phospholipase C-␥, and protein kinase C. 9, 31 We found that exogenous TRPC3 and TRPC6 proteins could associate with PKA and PDE3 in HEK293 cells ( Figure 5 ). However, endogenous TRPC6 preferentially forms a ternary complex with PKA and PDE3 rather than TRPC3 in RAoSMCs ( Figure 5 ). This makes it possible to induce local PKA-mediated phosphorylation of TRPC6 proteins by PDE3 inhibition. Although the position 1 phosphorylation site of human TRPC3 is not conserved in mouse TRPC3, PDE3 inhibition actually induced phosphorylation of TRPC3 at Ser251 and of TRPC7 at Ser267 ( Figure 5 ). As the inhibition of TRPC3 phosphorylation canceled suppression of TRPC3mediated Ca 2ϩ influx by PDE3 inhibition (Supplemental Figure VI) , our results indicate that the PKG phosphorylation sites of DAG-activated TRPC channels are also targets of PKA.
It has been thought that phosphorylation of MLCK is essential for the PKA-mediated vasodilating action. 39 However, the present results suggest that PKA induces vasodilation through 2 mechanisms: one is to suppress agonistinduced Ca 2ϩ influx through inhibition of DAG-activated TRPC channels, and the other is to inhibit MLCK activity by phosphorylation of MLCK. As PDE3 inhibition did not suppress the KCl-induced contraction, PKA-mediated inhibition of MLCK activity may not participate in the vasodilating effects of PDE3 inhibition. In addition, Rho functions as an essential mediator in agonist-induced vasoconstriction. 33, 39 Rho decreases myosin light chain phosphatase activity through Rho kinase-mediated phosphorylation. It has been reported that TRPC6-mediated Ca 2ϩ influx induces RhoA activation in thrombin-stimulated endothelial cells. 40 However, PDE3 inhibition did not attenuate agonist-induced Rho activation in RAoSMCs (Supplemental Figure VIII) . Thus, PDE3 inhibition may not affect the Rho-mediated signaling pathway.
Cilostazol has many pharmacological actions, including vasodilation, inhibition of platelet activation and aggregation, inhibition of thrombosis, increased blood flow to the limbs, improvement in serum lipids with lowering of triglycerides and elevation of high-density lipoprotein cholesterol, and inhibition of growth of VSMCs. 10 -12 Nakamura et al have previously reported the PKA-independent vasodilating effect of PDE3 inhibition using pressurized rabbit cerebral penetrating arterioles. 41 It is expected that the effectiveness of vasodilation by PDE3 inhibition is greatly dependent on the kinds of blood vessel sampled, the agonist stimulation, and the timing of drug treatment. Thus, our present study is only to show a novel mechanism underlying PKA-dependent vasodilation by PDE3 inhibition. Cilostazol is clinically applicable to the patients with intermittent claudication and arteriosclerosis obliteration. 10 -12 It is generally thought that endothelium-dependent vasodilation and capillary-like for-mation underlies protection of PDE3 inhibition against peripheral arterial disease. Although the relationship between TRPC channels and peripheral arterial disease is still unknown, our findings will provide a novel mechanism underlying endothelium-independent improvement of peripheral blood flow by PDE3 inhibition.
In conclusion, we demonstrated that PDE3 inhibition specifically suppresses DAG-mediated Ca 2ϩ influx through PKA-dependent phosphorylation of TRPC3/6/7 channels in HEK293 cells. Furthermore, DAG-activated TRPC6 channels were found to mediate the Ang II-induced contraction of aortic VSMCs, and PDE3 inhibition preferentially induced phosphorylation of rodent TRPC6 at Thr69. Formation of TRPC6/PDE3/PKA ternary complex may be involved in this mechanism. These findings will indicate the novel mechanism underlying the vasorelaxant effects of PDE3 inhibition against vasoactive hormones. 
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